Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma

NCT00038623 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma, Mantle-Cell

Interventions

DRUG: Yttrium-ibritumomab (Zevalin)
DRUG: Rituximab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]